Cite

HARVARD Citation

    Guidi, L. et al. (2019). Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterology journal. 7 (9), pp. 1189-1197. [Online]. 
  
Back to record